MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vir Biotechnology, Inc.

< Previous 1 2 3 Next >
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story